Acute kidney injury: New concepts in definition, diagnosis, pathophysiology, and treatment

Journal of the American Osteopathic Association

Volumn 109, Issue 1, 2009, Pages 13-19

  Lattanzio, Michael R ^a,c   Kopyt, Nelson P ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b Nephrology Hypertension Associates   (United States)

^c Department of Nephrology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACUTE KIDNEY FAILURE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COMPREHENSION; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; HEMODIALYSIS; HEPATORENAL SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL PRACTICE; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; PATHOPHYSIOLOGY; PROFESSIONAL PRACTICE; RENAL REPLACEMENT THERAPY; REVIEW;

COMPLEMENT SYSTEM PROTEINS; CONTRAST MEDIA; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, ACUTE; TERMINOLOGY AS TOPIC; URINE;

EID: 59949089785     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med. 1983;74:243-248.
2. Shusterman N, Strom BL, Murray TG, Morrison G, West SL, Maislin G. Risk factors and outcome of hospital-acquired acute renal failure. Clinical epidemiologic study. Am J Med. 1987;83:65-71.
3. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996;275:1489-1494.
4. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients [published online ahead of print September 21, 2005]. J Am Soc Nephrol. 2005;16:3365-3370.
5. Palevsky P, Murray PT, eds. Acute Kidney Injury and Critical Care Nephrology. Nephrology Self-Assessment Program (NephSAP). 2006;5:1-76.
6. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31. Available at: http://ccforum.com/content/11/2/R31. Accessed January 12, 2009.
7. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, and the Acute Dialysis Quality Initiative Workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group [review] [published online ahead of print May 24, 2004]. Crit Care. 2004;8:R204-R212. Available at: http://ccforum.com/contenf8/ 4ZR204. Accessed January 8, 2009.
8. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles [review] [published online ahead of print November 15, 2003]. Intensive Care Med. 2004;30:33-37.
9. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure [review]. Curr Opin Crit Care. 2002;8:509-514.
10. Abosaif NY, Tolba YA, Heap M, Russell J, El Nahas AM. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis. 2005;46:1038-1048.
11. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis [published online ahead of print May 12, 2006]. Crit Care. 2006;10:R73. Available at: http://ccforum.com/content/10/3/R73. Accessed December 8, 2008.
12. Zhou H, Hewitt SM, Yuen PST, Star RA. Acute kidney injury biomarkersneeds, present status, and future promise [editorial]. In: Palevsky P, Murray PT, eds. Acute Kidney Injury and Critical Care Nephrology. Nephrology Self-Assessment Program (NephSAP). 2006;5:63-70.
13. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221-226.
14. Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66:1115-1122.
15. Devarajan P. Neutrophil gelatinase-associated lipocalin-an emerging troponin for kidney injury [published online ahead of print September 22, 2008]. Nephrol Dial Transplant. 2008;23:3737-3743.
16. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury [published online ahead of print November 4, 2003]. Am J Physiol Renal Physiol. 2004;286:F552-F563.
17. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit [published online ahead of print September 7, 2005]. J Am Soc Nephrol. 2005;16:3046-3052.
18. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy [published correction appears in J Clin Invest. 2004;114:598]. J Clin Invest. 2004;114:5-14. Available at: http: //www.jci.org/articles/view/22353. Accessed December 8, 2008.
19. Marin E, Sessa WC. Role of endothelial-derived nitric oxide in hypertension and renal disease [review]. Curr Opin Nephrol Hypertens. 2007;16:105-110.
20. Pusey CD, Saltissi D, Bloodworth L, Rainford DJ, Christie JL. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. Q J Med. 1983;52:194-211.
21. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
22. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of highland low-osmolality iodinated contrast media. Radiology. 1993;188:171-178.
23. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies [published online ahead of print March 13, 2007]. Circulation. 2007;115:1211-1217.
24. From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic [published online ahead of print December 5, 2007]. Clin J Am Soc Nephrol. 2008;3:10-18.
25. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis [review]. J Clin Invest. 2003;112:460-467. Available at: http://www.jci.org/articles/view/ 19523. Accessed December 8, 2008.
26. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117-123.
27. Schrier RW. Acute renal failure and sepsis [review]. N Engl J Med. 2004;351:159-169.
28. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
29. De Vriese AS. Prevention and treatment of acute renal failure in sepsis [review]. J Am Soc Nephrol. 2003;14:792-805.
30. van Bommel E, Bouvy ND, So KL, Zietse R, Vincent HH, Bruining HA, et al. Acute dialytic support for the critically ill: intermittent hemodialysis versus continuous arteriovenous hemodiafiltration. Am J Nephrol. 1995;15:192-200.
31. Gines P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol. 1999:10:1833-1839.
32. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis. 2008;197:1548-1557. Available at: http//www.pubmedcentral.nih.gov/articlerender.fcgi?tool= pubmed&pubmedi d=18422458. Accessed January 9, 2009.
33. Fine D. Renal disease and toxicities: issues for HIV care providers. Top HIV Med. 2007;14:164-169.
34. Harris MI. Noninsulin-dependent diabetes mellitus in black and white Americans [review]. Diabetes Metab Rev. 1990;6:71-90.
35. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
36. Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in diagnoses of HIV/AIDS-33 states, 2001-2005. MMWR Morb Mortal Wkly Rep. 2007;56:189-193. Available at: http://www.cdc.gov/mmwr/preview/ mmwr html/mm5609a1.htm. Accessed January 12, 2009.
37. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006;20:1019-1026.
38. Nochy D, Glotz D, Dosquet P, Pruna A, Guettier C, Weiss L, et al. Renal disease associated with HIV infection: a multicentric study of 60 patients fromParis hospitals. Nephrol Dial Transplant. 1993;8:11-19.
39. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scle-romyxoedema-like cutaneous disease in renal-dialysis patients. Lancet. 2000;356:1000-1001.
40. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing der-mopathy with systemic involvement. Arch Dermatol. 2003;139:903-906.
41. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link [published online ahead of print February 7, 2007]? Clin J Am Soc Nephrol. 2007;2:200-202.
42. US Food and Drug Administration. Information for healthcare professionals gadolinium-based contrast agents for magnetic resonance imaging scans (marketed as Omniscan, OptiMARK, Magnevist, ProHance, and Multi-Hance) [FDA alert]. Rockville, Md: US Food and Drug Administration; 2006. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca-2006 12HCP.htm. Accessed December 15, 2008.
43. Star RA. Treatment of acute renal failure [review]. Kidney Int. 1998;54:1817-1831.
44. Miller SB, Martin DR, Kissane J, Hammerman MR. Rat models for clinical use of insulin-like growth factor I in acute renal failure. Am J Physiol. 1994;266(6 pt 2):F949-F956.
45. Miller SB, Martin DR, Kissane J, Hammerman MR. Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat. Proc Natl Acad Sci USA. 1992;89:11876-11880. Available at: http://www.pubmed central.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=1465411. Accessed January 12, 2009.
46. Goes N, Urmson J, Vincent D, Ramassar V, Halloran PF. Effect of recom-binant human insulin-like growth factor-1 on the inflammatory response to acute renal injury. J Am Soc Nephrol. 1996;7:710-720.
47. Kopple JD, Hirschberg R, Guler H-P, Pike M; and Chiron Study Group. Lack of effect of recombinant human insulin-like growth factor I (IGF I) in patients with acute renal failure (ARF) [abstract]. J Am Soc Nephrol. 1996;7:1375.
48. Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int. 2000;57:293-298.
49. Rahman SN, Kim GE, Mathew AS, Goldberg CA, Allgren R, Schrier RW, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. 1994;45:1731-1738.
50. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med. 1996;101:49-53.
51. Conger JD. Interventions in clinical acute renal failure: what are the data [review]? Am J Kidney Dis. 1995;26:565-576.
52. Kellum JA. Use of diuretics in the acute care setting [review]. Kidney Int Suppl. 1998;66:S67-S70.
53. Rialp G, Roglan A, Betbesé AJ, Pérez-Márquez M, Ballús J, López-Velarde G, et al. Prognostic indexes and mortality in critically ill patients with acute vrenal failure treated with different dialytic techniques. Ren Fail. 1996;18:667- 675.